Dashboard
1
Flat results in Mar 25
- INTEREST COVERAGE RATIO(Q) Lowest at 2,561.21
- DEBT-EQUITY RATIO (HY) Highest at -5.08 %
- INTEREST(Q) Highest at CNY 1.34 MM
2
With ROE of 9.77%, it has a expensive valuation with a 3.27 Price to Book Value
3
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,390 Million (Small Cap)
33.00
NA
1.50%
0.07
9.77%
3.27
Revenue and Profits:
Net Sales:
143 Million
(Quarterly Results - Jun 2025)
Net Profit:
9 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.4%
0%
0.4%
6 Months
9.02%
0%
9.02%
1 Year
-2.32%
0%
-2.32%
2 Years
13.34%
0%
13.34%
3 Years
-23.9%
0%
-23.9%
4 Years
-41.92%
0%
-41.92%
5 Years
-39.15%
0%
-39.15%
Shanghai Aladdin Biochemical Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
22.34%
EBIT Growth (5y)
37.31%
EBIT to Interest (avg)
81.15
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.07
Sales to Capital Employed (avg)
0.32
Tax Ratio
9.80%
Dividend Payout Ratio
55.91%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
17.10%
ROE (avg)
9.56%
Valuation key factors
Factor
Value
P/E Ratio
33
Industry P/E
Price to Book Value
3.27
EV to EBIT
27.27
EV to EBITDA
21.22
EV to Capital Employed
3.13
EV to Sales
6.14
PEG Ratio
NA
Dividend Yield
1.50%
ROCE (Latest)
11.47%
ROE (Latest)
9.77%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
143.20
138.30
3.54%
Operating Profit (PBDIT) excl Other Income
33.70
51.30
-34.31%
Interest
12.80
0.60
2,033.33%
Exceptional Items
-0.00
-0.10
100.00%
Consolidate Net Profit
9.10
36.00
-74.72%
Operating Profit Margin (Excl OI)
169.00%
281.60%
-11.26%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 3.54% vs 40.69% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -74.72% vs 162.77% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
527.20
400.00
31.80%
Operating Profit (PBDIT) excl Other Income
170.30
118.20
44.08%
Interest
8.40
7.30
15.07%
Exceptional Items
0.40
1.40
-71.43%
Consolidate Net Profit
115.70
85.80
34.85%
Operating Profit Margin (Excl OI)
243.40%
230.40%
1.30%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 31.80% vs 6.72% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 34.85% vs -7.54% in Dec 2023
About Shanghai Aladdin Biochemical Technology Co., Ltd. 
Shanghai Aladdin Biochemical Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






